Holding ANDA Labeling Review Until Late Cycle Could Minimize Delays From Last-Minute Changes

Clock near deadline
FDA agreed to issue the ANDA labeling assessment closer to the goal date in order to avoid delays from late changes by reference product sponsors. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics